Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Humacyte, Inc.NASDAQ: HUMA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $495K fell 4.3% year over year, ahead of the -74.0% change in trailing-twelve-month revenue. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $4.03M (+97.6%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $495K+6.0% QoQ
- Last fiscal yearDec 2025
- $2.04M— YoY
- LTMMar 2026
- $2.02M-74.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.3% | +245.5% | +249.8 pp |
| 1 year | — | +97.6% | — |
| 3-year CAGR | +9.2% | +283.4% | +274.2 pp |
| 5-year CAGR | +176.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 2.04M USD
- Year-over-year change
- —
- 4-year CAGR
- +12.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.04M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 1.57M | +23.9% |
| FY2021 | 2021-12-31 | 1.26M | — |
Revenue vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 revenue of $2.02M is the 6th highest of the 11 companies compared; the peer median is $2.87M.
- Its year-over-year change of -74.0% is the 5th highest of 6, against a peer median of -45.5%.
- Over three fiscal years its annual growth of +9.2% compares with a peer median of -2.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $217.78M | +8.2% | -5.3% | |
| LTM Mar 2026 | $45.35M | -66.4% | -31.1% | |
| LTM Mar 2026 | $36.49M | -45.5% | -0.4% | |
| LTM Mar 2026 | $28.22M | +20.1% | +17.1% | |
| LTM Mar 2026 | $5.74M | -96.7% | — | |
| LTM Mar 2026 | $2.02M | -74.0% | +9.2% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding HUMA) | $2.87M | -45.5% | -2.9% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.